Lineage Cell Therapeutics remains a high-risk, milestone-dependent biotechnology firm whose valuation is tethered to the success of its Roche/Genentech partnership rather than recurring commercial revenue. While the company maintains gross margins frequently e...
Price trend, volume and key moving averages
Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.03-5.9% vs -$0.03 | $1M-42.0% vs $2M |
Q2 2026 May 12, 2026 | -$0.03-50.0% vs -$0.02 | $2M-52.1% vs $4M |
Q2 2026 Mar 5, 2026 | $0.00+109.2% vs -$0.04 | $7M+236.8% vs $2M |
Q4 2025 Nov 6, 2025 | -$0.13-550.0% vs -$0.02 | $4M+87.8% vs $2M |
Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) shares were up 8.7% during trading on Friday. The company traded as high as $1.04 and last traded at $1.03. Approximately 2,480,587 shares traded hands during trading, an increase of 101% from the average daily volume of 1,231,612 shares. The stock had previously closed at $0.9478.
CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--AlloSCOPE 5D Patent Release.
Lineage Cell Therapeutics NYSEAMERICAN: LCTX outlined progress across its cell-therapy pipeline during its second-quarter 2026 earnings call, highlighting preclinical advances in corneal disease, Type 1 diabetes and hearing loss programs while Roche and Genentech continue surgical-delivery optimization work for its lead OpRegen program.
Lineage Cell Therapeutics, Inc. (LCTX) Q2 2026 Earnings Call Transcript
Benchmark LCTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Lineage Cell Therapeutics, Inc. (LCTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.00 | $249.3M | -3.57 | 53.24% | -436.47% | -105.57% | — | |
| $2.11 | $245.94M | -1.83 | -51.24% | -1941.09% | -65.08% | — | |
| $11.21 | $1.26B | -2.94 | 16.92% | -672.16% | -57.79% | — | |
| $24.05 | $2.47B | -29.69 | 120.01% | -54.75% | -7.7% | — | |
| $2.40 | $368.31M | -1.33 | 25.39% | -157.32% | -196.63% | — | |
| $49.39 | $4.76B | -7.63 | -89.97% | -3368.72% | -24.39% | — |
Lineage Cell Therapeutics, Inc. (LCTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Lineage Cell Therapeutics, Inc. (LCTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 12, 2026·SEC
May 12, 2026·SEC
Get notified when LCTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lineage Cell Therapeutics, Inc. (LCTX) stock FAQ — growth, dividends, profitability & financials explained
Lineage Cell Therapeutics, Inc. (LCTX) reported $13.1M in revenue for fiscal year 2025. This represents a 12983% increase from $0.1M in 1996.
Lineage Cell Therapeutics, Inc. (LCTX) grew revenue by 53.2% over the past year. This is strong growth.
Lineage Cell Therapeutics, Inc. (LCTX) reported a net loss of $32.3M for fiscal year 2025.
Lineage Cell Therapeutics, Inc. (LCTX) has a return on equity (ROE) of -105.6%. Negative ROE indicates the company is unprofitable.
Lineage Cell Therapeutics, Inc. (LCTX) had negative free cash flow of $23.9M in fiscal year 2025, likely due to heavy capital investments.
